• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.靶向癌症治疗及其眼部副作用：综述
J Immunother Precis Oncol. 2021 Feb 25;4(1):6-15. doi: 10.36401/JIPO-20-21. eCollection 2021 Feb.
2
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.免疫检查点抑制剂的眼部不良反应：梅奥诊所的经验。
Br J Ophthalmol. 2021 Sep;105(9):1263-1271. doi: 10.1136/bjophthalmol-2020-316970. Epub 2020 Aug 23.
3
Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.美国眼科学会智能研究视野注册中心记录的抗 CTLA-4 或 PD-1 治疗后的眼部免疫相关不良事件。
Ophthalmology. 2021 Jun;128(6):910-919. doi: 10.1016/j.ophtha.2020.11.001. Epub 2020 Nov 6.
4
Ocular surface disease associated with immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗相关的眼表面疾病。
Ocul Surf. 2021 Apr;20:115-129. doi: 10.1016/j.jtos.2021.02.004. Epub 2021 Feb 19.
5
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.检查点抑制剂免疫治疗：全身适应证和眼部不良反应。
Retina. 2018 Jun;38(6):1063-1078. doi: 10.1097/IAE.0000000000002181.
6
Ocular and systemic adverse effects of ophthalmic and non ophthalmic medications.眼科和非眼科药物的眼部及全身不良反应。
Proc West Pharmacol Soc. 2011;54:69-72.
7
Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma.皮肤恶性黑色素瘤患者的靶向治疗和免疫治疗的眼部副作用。
Eur J Ophthalmol. 2021 May;31(3):1391-1398. doi: 10.1177/1120672120930688. Epub 2020 May 31.
8
Overview of Ocular Side Effects of Selinexor.Selinexor 的眼部副作用概述。
Oncologist. 2021 Jul;26(7):619-623. doi: 10.1002/onco.13756. Epub 2021 Apr 8.
9
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.靶向治疗与免疫治疗的进展——未来十年非小细胞肺癌的治疗将如何改变：一项叙述性综述
Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.
10
Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center.美国一家三级癌症中心免疫检查点抑制剂眼部毒性研究亮点
J Immunother Precis Oncol. 2022 Nov 30;5(4):98-104. doi: 10.36401/JIPO-22-14. eCollection 2022 Nov.

引用本文的文献

1
p53 prophylactic therapy for cancer prevention.用于癌症预防的p53预防性治疗。
Cell Death Differ. 2025 Jun 25. doi: 10.1038/s41418-025-01538-z.
2
Assessment of retinal, choroidal and peripapillary microvascular changes in patients with chronic myeloid leukemia.慢性髓性白血病患者视网膜、脉络膜及视乳头周围微血管变化的评估
Jpn J Ophthalmol. 2025 May 26. doi: 10.1007/s10384-025-01216-0.
3
Xihuang pill induces pyroptosis and inhibits progression of breast cancer cells via activating the cAMP/PKA signalling pathway.西黄丸通过激活cAMP/PKA信号通路诱导乳腺癌细胞焦亡并抑制其进展。
Am J Cancer Res. 2023 Apr 15;13(4):1347-1362. eCollection 2023.
4
Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center.美国一家三级癌症中心免疫检查点抑制剂眼部毒性研究亮点
J Immunother Precis Oncol. 2022 Nov 30;5(4):98-104. doi: 10.36401/JIPO-22-14. eCollection 2022 Nov.
5
Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma.一名老年多发性骨髓瘤女性使用isatuximab后出现出血性结膜水肿
Cureus. 2022 Mar 2;14(3):e22764. doi: 10.7759/cureus.22764. eCollection 2022 Mar.

本文引用的文献

1
Photopsias in the Setting of Nivolumab Therapy.纳武单抗治疗背景下的光幻视
J Neuroophthalmol. 2021 Mar 1;41(1):e25-e26. doi: 10.1097/WNO.0000000000000909.
2
Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.达拉非尼和曲美替尼治疗转移性黑色素瘤后发生重症肌无力。
Neurology. 2020 Feb 18;94(7):322-323. doi: 10.1212/WNL.0000000000008860. Epub 2019 Dec 30.
3
Pembrolizumab-Related Enophthalmos.帕博利珠单抗相关的眼球内陷。
Ophthalmology. 2020 Jan;127(1):121. doi: 10.1016/j.ophtha.2019.09.031.
4
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.免疫检查点抑制剂相关重症肌无力：单中心经验和文献系统评价。
J Immunother Cancer. 2019 Nov 21;7(1):319. doi: 10.1186/s40425-019-0774-y.
5
Diagnosis and Management of Rare Immune-Related Adverse Events.罕见免疫相关不良事件的诊断与管理。
Oncologist. 2020 Jan;25(1):6-14. doi: 10.1634/theoncologist.2019-0083. Epub 2019 Nov 6.
6
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.帕博利珠单抗诱发眼内压过低伴近乎完全失明、间质性肺纤维化和关节炎。
Front Oncol. 2019 Sep 23;9:944. doi: 10.3389/fonc.2019.00944. eCollection 2019.
7
Ocular adverse events with immune checkpoint inhibitors.免疫检查点抑制剂相关的眼部不良事件。
J Curr Ophthalmol. 2019 Jun 11;31(3):319-322. doi: 10.1016/j.joco.2019.05.002. eCollection 2019 Sep.
8
A rare case of Miller Fisher variant of Guillain-Barr Syndrome (GBS) induced by a checkpoint inhibitor.1例由检查点抑制剂诱发的吉兰-巴雷综合征（GBS）的米勒-费希尔变异型罕见病例。
BMJ Case Rep. 2019 Aug 13;12(8):e229443. doi: 10.1136/bcr-2019-229443.
9
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report.与曲妥珠单抗-美坦新偶联物（Kadcyla®，T-DM1）给药相关的泪液引流系统狭窄：一例报告。
BMC Cancer. 2019 Aug 6;19(1):774. doi: 10.1186/s12885-019-5986-5.
10
Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.帕博利珠单抗相关的全身性肌炎累及眼肌和颈后肌，类似于重症肌无力：病例报告。
BMC Neurol. 2019 Aug 5;19(1):184. doi: 10.1186/s12883-019-1416-1.

靶向癌症治疗及其眼部副作用：综述

Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

作者信息

Bindiganavile Shruthi Harish, Bhat Nita, Lee Andrew G, Gombos Dan S, Al-Zubidi Nagham

机构信息

Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.

The Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.

出版信息

J Immunother Precis Oncol. 2021 Feb 25;4(1):6-15. doi: 10.36401/JIPO-20-21. eCollection 2021 Feb.

DOI:10.36401/JIPO-20-21
PMID:35664825
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9161666/
Abstract

Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.

摘要

靶向癌症治疗药物是癌症治疗领域的最新进展。尽管其应用范围不断扩大，但在使用癌症治疗药物时经常会出现眼部副作用。本综述描述了靶向癌症治疗药物的眼部副作用。